NEWS

Commonsense Policies Needed to Lower Healthcare Costs and Improve Patient Access While Protecting Drug Development Pipeline

Today, President Biden highlighted the administration’s current and future efforts to lower healthcare costs. The good news is recent...

Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma

We Work For Health recently convened a conversation to explore the impact policy decisions have on the biopharmaceutical industry and...

Vendors Power America's Biopharmaceutical Industry

We Work For Health recently released new employment, vendor and supplier expenditure data that showcases the vital contributions of these...

President Biden’s State of the Union Call for IRA Expansion Hurts Patients, Workers, and U.S. Leadership

During his State of the Union address Thursday night, President Biden called for Congress to expand the Inflation Reduction Act to...

House Reviews the ORPHAN Cures Act

On Feb. 29, the House Energy and Commerce Subcommittee on Health held a hearing to review a number of bills that impact those living with...

Biden's Attempts to Lower Drug Costs Are Sabotaging Biosimilar Competition and Are Destined For Failure

The FDA approved 55 new drugs in 2023 — up substantially from 2022's 37 approvals, and barely behind the all-time record of 59 set in...